SSRIs (fluoxetine, sertraline, escitalopram) are the standard starting point for most people with depression. SNRIs, bupropion, and mirtazapine are established alternatives with different side effect profiles. Older classes — TCAs and MAOIs — are still used when newer medications fail. All antidepressants take 4–6 weeks to show meaningful benefit.
Medications for Depression: A Plain-English Guide
Major depressive disorder affects tens of millions of Americans, and medication is a core part of treatment for moderate to severe cases. Yet antidepressants are often misunderstood — as "happy pills" that work immediately, or as fundamentally habit-forming. Neither is accurate. This guide explains the major classes of antidepressant medications, how each one works, what distinguishes them from each other, and why they all share a frustrating delay before they help.
Depression is now understood as a disorder involving multiple brain systems — not simply a deficit of serotonin, as was once the dominant narrative. Different drug classes target different neurotransmitter systems, and the best choice depends on a patient's symptom profile, other health conditions, and prior treatment history.
Drug Classes Used for Depression
SSRIs are the standard first-line antidepressants for most patients. They block the reuptake of serotonin, keeping more of it active in the synaptic gap between neurons. SSRIs are not necessarily more effective than older antidepressants, but they are significantly better tolerated and far safer in overdose — the key reason they replaced tricyclics as first-line therapy. Escitalopram and sertraline consistently rank among the best-tolerated in head-to-head comparisons. Fluoxetine has the longest half-life of the class, making missed doses less disruptive and discontinuation easier. Paroxetine causes more weight gain and is harder to taper than others in the class.
SNRIs block reuptake of both serotonin and norepinephrine. The norepinephrine component can improve energy, motivation, and concentration — symptoms that SSRIs sometimes address less effectively. Duloxetine has FDA approval not only for depression but also for generalized anxiety disorder, diabetic neuropathy, and chronic musculoskeletal pain, making it a useful choice when these conditions co-occur with depression. Venlafaxine is potent but can be difficult to discontinue; gradual tapering is essential. Both SNRIs may raise blood pressure slightly, which should be monitored.
Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) — chemically unrelated to SSRIs and SNRIs. It does not affect serotonin at all, which gives it a distinct side effect profile: notably, it does not cause the sexual dysfunction or weight gain commonly associated with SSRIs. It is sometimes activating and can worsen anxiety in some patients. Bupropion is also FDA-approved for smoking cessation (as Zyban). It is contraindicated in patients with seizure disorders or active eating disorders, as it lowers the seizure threshold. It is a strong option for patients with fatigue-predominant depression or those who cannot tolerate SSRI side effects.
Mirtazapine works through a completely different mechanism from SSRIs: it blocks certain norepinephrine and serotonin receptors, which indirectly increases release of both neurotransmitters. It also powerfully blocks histamine receptors, causing significant sedation and increased appetite — properties that are side effects in some patients but therapeutic advantages in others. It is often an excellent choice for patients with depression accompanied by significant insomnia, poor appetite, or weight loss. Paradoxically, lower amounts tend to be more sedating; higher amounts are less so due to additional receptor activity that counteracts the histamine effect.
Tricyclics were the first widely used antidepressants, developed in the 1950s. They block reuptake of serotonin and norepinephrine but also interact with many other receptors (histamine, muscarinic, alpha-adrenergic), producing a broad side effect burden including sedation, dry mouth, constipation, urinary retention, and orthostatic hypotension. Most significantly, they are dangerous in overdose — a major concern in depression treatment — which is why they were largely replaced by SSRIs. They remain clinically useful for patients who have failed multiple newer agents, for neuropathic pain (amitriptyline is widely used for this), and for certain other conditions.
MAOIs are the oldest class of antidepressants and the most powerful for certain treatment-resistant cases. They work by blocking the enzyme that breaks down serotonin, norepinephrine, and dopamine, dramatically increasing levels of all three. The serious limitation is the "tyramine interaction": MAOIs combined with tyramine-rich foods (aged cheeses, cured meats, fermented foods) or many other medications can cause a hypertensive crisis — a sudden, dangerous spike in blood pressure. This dietary restriction and the extensive drug interaction profile make MAOIs a last-resort option, used when multiple other treatments have failed. The selegiline patch (Emsam) has a somewhat more manageable profile at lower levels.
How Doctors Choose Which Antidepressant
The first decision is almost always an SSRI unless there is a specific reason to choose otherwise. The specific SSRI is selected based on the patient's symptom profile (anxiety-heavy depression may favor escitalopram; fatigue-heavy may favor bupropion as an alternative), comorbidities, potential drug interactions, and prior treatment history. If a patient has tried an SSRI before and had a poor response, switching to a different class (SNRI or bupropion) is often more productive than trying another SSRI.
Augmentation strategies — adding a second medication to an antidepressant that is partially working — are common. Options include atypical antipsychotics like aripiprazole or quetiapine, lithium, buspirone, or thyroid hormone. When two or three adequate trials have failed, the label "treatment-resistant depression" applies and specialized approaches including esketamine (Spravato), electroconvulsive therapy (ECT), or transcranial magnetic stimulation (TMS) may be considered.
Why Antidepressants Take 4–6 Weeks to Work
This is one of the most commonly misunderstood aspects of antidepressant treatment. SSRIs increase serotonin availability within hours of the first dose — yet clinical depression does not improve for weeks. The explanation is that the immediate neurotransmitter change is not what produces the antidepressant effect. Rather, the sustained increase in serotonin triggers a cascade of slower adaptations: receptor density changes, alterations in gene expression, and — in what may be the most significant finding — neuroplasticity changes including the growth of new neurons in the hippocampus. These adaptations require weeks to accumulate. This is why stopping an antidepressant after two weeks because it "isn't working" is premature; a minimum of four to six weeks at an adequate amount is required before the response can be evaluated.
All antidepressants carry an FDA black box warning about increased risk of suicidal thoughts in children, adolescents, and young adults under 25, particularly in the first few weeks of treatment. This does not mean antidepressants cause suicide — untreated depression itself carries risk — but close monitoring in early treatment is essential.
Frequently Asked Questions
Why do antidepressants take 4 to 6 weeks to work?
Antidepressants change neurotransmitter levels within hours, but mood improvement lags significantly. The leading explanation is that the therapeutic effect comes not from the immediate neurotransmitter increase but from slower downstream adaptations — changes in receptor sensitivity, gene expression, and neuroplasticity (including hippocampal neurogenesis) that accumulate over weeks. The drug is working from day one; the brain changes it induces take time to translate into mood improvement.
Are antidepressants addictive?
Antidepressants are not addictive — they do not cause craving, euphoria, or compulsive drug-seeking behavior. However, stopping them abruptly, especially shorter-acting drugs like paroxetine and venlafaxine, can cause discontinuation symptoms: flu-like feelings, "brain zaps," dizziness, and irritability. This is physical dependence, not addiction, and it is managed with a gradual taper rather than abrupt discontinuation.
What if the first antidepressant doesn't work?
Studies suggest roughly half of patients achieve remission with their first antidepressant. For those who do not, options include switching to a different drug (within the class or to a different class entirely), augmenting the current medication with a second agent, or pursuing alternative treatments. It typically takes multiple trials to find an optimal regimen — this is a normal part of depression treatment, not a sign that medication cannot help.
Need to identify a pill by its imprint, shape, or color?
Use the PillID Pill Identifier →